Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Soper, JT, Havrilesky, LJ, Secord, AA, Berchuck, A, and Clarke-Pearson, DL. "Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery." Int J Gynecol Cancer 15, no. 3 (May 2005): 542-548.

Full Text

Havrilesky, LJ, Kulasingam, SL, Matchar, DB, and Myers, ER. "FDG-PET for management of cervical and ovarian cancer." Gynecol Oncol 97, no. 1 (April 2005): 183-191.

Full Text

Skates, SJ, Horick, N, Yu, Y, Xu, F-J, Berchuck, A, Havrilesky, LJ, de Bruijn, HWA, van der Zee, AGJ, Woolas, RP, Jacobs, IJ, Zhang, Z, and Bast, RC. "Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions." J Clin Oncol 22, no. 20 (October 15, 2004): 4059-4066.

Full Text

Havrilesky, LJ, Leath, CA, Huh, W, Calingaert, B, Bentley, RC, Soper, JT, and Alvarez Secord, A. "Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer." Gynecol Oncol 93, no. 2 (May 2004): 429-434.

Full Text

Lancaster, JM, Dressman, HK, Whitaker, RS, Havrilesky, L, Gray, J, Marks, JR, Nevins, JR, and Berchuck, A. "Gene expression patterns that characterize advanced stage serous ovarian cancers." J Soc Gynecol Investig 11, no. 1 (January 2004): 51-59.

Scholars@Duke

Havrilesky, L, Darcy, KM, Hamdan, H, Priore, RL, Leon, J, Bell, J, Berchuck, A, and Gynecologic Oncology Group Study, . "Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study." J Clin Oncol 21, no. 20 (October 15, 2003): 3814-3825.

Full Text

Roth, TM, Secord, AA, Havrilesky, LJ, Jones, E, and Clarke-Pearson, DL. "High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease." Gynecol Oncol 91, no. 1 (October 2003): 258-260.

Scholars@Duke

Havrilesky, LJ, Peterson, BL, Dryden, DK, Soper, JT, Clarke-Pearson, DL, and Berchuck, A. "Predictors of clinical outcomes in the laparoscopic management of adnexal masses." Obstet Gynecol 102, no. 2 (August 2003): 243-251.

Scholars@Duke

Jones, EL, Samulski, TV, Dewhirst, MW, Alvarez-Secord, A, Berchuck, A, Clarke-Pearson, D, Havrilesky, LJ, Soper, J, and Prosnitz, LR. "A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma." Cancer 98, no. 2 (July 15, 2003): 277-282.

Full Text

Havrilesky, LJ, Wong, TZ, Secord, AA, Berchuck, A, Clarke-Pearson, DL, and Jones, EL. "The role of PET scanning in the detection of recurrent cervical cancer." Gynecol Oncol 90, no. 1 (July 2003): 186-190.

Scholars@Duke

Pages